Add time:08/30/2019         Source:sciencedirect.com

ObjectivePatients with bladder cancer have responded poorly to oxaliplatin therapy in clinical trials. Blockade of receptor tyrosine kinases is considered a good strategy in cancer therapy. Our previous studies have demonstrated the crucial roles of brain-derived neurotrophic factor and its receptor tropomyosin receptor kinase B (TrkB) in transitional cell carcinoma (TCC). The aim of this study was to examine the cytotoxic effects of lestaurtinib, a new pan-Trk inhibitor, and oxaliplatin on bladder cancer cell lines.

We also recommend Trading Suppliers and Manufacturers of Lestaurtinib (cas 111358-88-4). Pls Click Website Link as below: cas 111358-88-4 suppliers